If you’re a patient or caregiver please get in touch
Thank you for your interest in AviadoBio
We are currently enrolling people with a genetic sub-type of frontotemporal dementia (FTD-GRN) into our ASPIRE-FTD Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of our investigational* gene therapy, AVB-101, which is designed as a one-time treatment to halt disease progression delivered by intrathalamic infusion.
For more information on ASPIRE-FTD including a list of active clinical sites please visit clinicaltrials.gov.
You can also contact us by phone +44 (0) 203 089 7917 or via email email@example.com.
*Investigational therapy means that the therapy has not been approved by any regulatory authority and no regulatory authority has determined the therapy to be safe and effective to treat FTD-GRN or any other condition.